Drug Profile
Research programme: histone deacetylase inhibitors - ExonHit Therapeutics
Alternative Names: EHT 0205; EHT 205Latest Information Update: 21 Aug 2009
Price :
$50
*
At a glance
- Originator ExonHit Therapeutics
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer
Most Recent Events
- 21 Aug 2009 Discontinued - Preclinical for Alzheimer's disease in France (unspecified route)
- 21 Aug 2009 Discontinued - Preclinical for Cancer in France (unspecified route)
- 14 Jul 2006 Preclinical trials in Alzheimer's disease in France (unspecified route)